[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"headache-migraine\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:headache-migraine":276},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,57,110,136,157,183,205,225,255],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":12,"acronym":4,"eligibilityCriteria":13,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":17,"targetDuration":4,"studyType":20,"phases":21,"briefSummary":23,"conditions":24,"keywords":33,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":45,"lastUpdatePostDateStruct":46,"startDateStruct":49,"completionDateStruct":51,"leadSponsor":53,"locationsCount":56},"100417438",false,"NCT04715685","Mind Body Balance for Pediatric Migraine","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura or chronic migraine that meets the International Classification of Headache Disorders(ICHD) criteria\n* Frequency: Headache frequency based upon prospective headache diary of 28 days must be ≥ 4 and ≤ 28.\n* PedMIDAS: PedMIDAS Disability Score \\> 4, indicating at least mild disruption in daily activities and \\\u003C 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Use of one or more of the following prescribed nutraceuticals and\u002For preventive anti-migraine medications at the time or randomization or be on a stable dose of one or more of the following throughout the 12 weeks of the study \\[Vitamin B2 (Riboflavin), Co-Q 10 (Coenzyme Q10), Magnesium (Mg), Vitamin D2 or D3 (Erocalciferol\u002FCholecalciferol), Depakote (Divalproate), Inderal (Propanerol), Elavil ((Amitripyline), Topamax (Topiramate), Periactin (Cyproheptadine)\\]\n* Language: English speaking, able to complete interviews and questionnaires in English\n\nExclusion Criteria:\n\n* Continuous migraine defined as unrelenting headache for a 28 day period\n* Must agree not to take non-specific acute medication, such as NSAIDS (e.g., ibuprofen), more than 3 times per week, or migraine specific acute medications, such as triptans, more than 6 times per month (to prevent medication overuse headache)\n* PedMIDAS Disability Score \\> 140, indicating extreme disability that may require more comprehensive, multi-component therapy\n* Youth who are pregnant, or those who are sexually active and not using a medically accepted form of contraception (barrier or hormonal methods)\n* Present severe psychiatric disease, alcohol or drug dependence, or documented developmental delays or impairments (e.g., autism, cerebral palsy, or mental retardation) or other circumstances, that, in the opinion of the investigator, would interfere with adherence to study requirements or safe participation in the study","ALL","10 Years","17 Years",{"count":18,"type":19},260,"ESTIMATED","INTERVENTIONAL",[22],"NA","This study uses a factorial research design to evaluate a nurse delivered mind body intervention using different doses of 3 treatment components to determine the optimized treatment for headache day reduction.",[25,26,27,28,29,30,31,32],"Headache","Headache Disorders","Headache, Migraine","Migraine","Migraine Disorders","Migraine With Aura","Migraine Without Aura","Chronic Migraine",[34,35,36,37,38,39,40,41,42,43],"headache","migraine","cognitive behavioral therapy","pediatrics","mind body intervention","diaphragmatic breathing","progressive muscle relaxation","imagery","relaxation","biofeedback","RECRUITING","2026-06-14",{"date":47,"type":48},"2026-06-16","ACTUAL",{"date":50,"type":48},"2021-03-09",{"date":52,"type":19},"2026-11-30",{"name":54,"class":55},"Children's Hospital Medical Center, Cincinnati","OTHER",2,{"id":58,"slug":4,"hasResults":10,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":4,"eligibilityCriteria":62,"healthyVolunteers":10,"sex":63,"minAge":64,"maxAge":65,"enrollmentInfo":66,"targetDuration":4,"studyType":20,"phases":68,"briefSummary":69,"conditions":70,"keywords":81,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":100,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":109},"100571149","NCT06716489","Aerobic Exercise and Its Impact on Sensory, Musculoskeletal, and Psychosocial Aspects in Migraine","Influence of Aerobic Exercise on Sensory Perception, Musculoskeletal and Psychosocial Alterations in Patients With Migraine","Inclusion Criteria:\n\n* Women aged between 18 and 48 years.\n* Diagnosed with migraine by an experienced neurologist specialized in headaches, following the criteria of the International Classification of Headache Disorders (ICHD).\n* Frequency of headache between 3 and 8 days per month, to ensure adherence to the treatment.\n\nExclusion Criteria:\n\n* Presence of any other type of concurrent headache.\n* Medical conditions affecting sensitivity and autonomic modulation, such as peripheral neuropathies, autonomic disorders, severe neurological diseases, and others.\n* Conditions that prevent physical activity, such as severe musculoskeletal injuries, cardiovascular diseases, or related conditions.\n* Premature ovarian failure.\n* Regular physical exercise in the past year.\n* Body Mass Index (BMI) above 30.0.\n* Smokers or individuals using drugs that interfere with sensitivity and cardiac modulation (e.g., beta-blockers).\n* Abuse of abortive medications.","FEMALE","18 Years","48 Years",{"count":67,"type":19},100,[22],"Migraine is a neurological disorder associated with high levels of disability and changes in sensory processing, musculoskeletal function, and psychosocial factors. Aerobic exercise is a low-cost, non-pharmacological strategy that has shown potential benefits for migraine management, but its effects on sensory perception and musculoskeletal function are not yet fully understood.\n\nThis randomized controlled trial will investigate the effects of a supervised aerobic exercise program combined with pain neuroscience education compared with an active control condition in women aged 18 to 48 years diagnosed with migraine. Participants will be randomly allocated to either an intervention group, which will perform supervised aerobic exercise three times per week for 16 weeks and receive one session of pain neuroscience education, or a control group, which will receive recommendations for unsupervised physical activity at home.\n\nOutcomes related to migraine-related disability, self-reported symptoms, sensory sensitivity, and musculoskeletal function will be assessed at baseline and after the intervention period. Questionnaires will also be collected at a 6-month follow-up. The results of this study may contribute to the development of accessible and low-risk non-pharmacological treatment strategies for people with migraine.",[28,71,72,73,25,74,26,75,76,77,78,79,80],"Migraine Disease","Migraine Disorder","Migraine Disorders, Brain","Headache (Migraine)","Headache Disorders, Primary","Aerobic Exercise","Pain Management","Sensory Disorders","Psychosocial Factors","Quality of Life",[35,82,83,84,34,85,86,87,88,89,90,79,91,92,93,94,95,96,97,98,99],"aerobic exercise","sensory perception","exercise","disability","musculoeskeletal alterations","quality of life","neck pain","cervical pain","Sensory Thresholds","Physical Fitness","Exercise Intervention","Central Sensitization","Physical Therapy","Migraine Management","Non-pharmacological Treatment","Clinical Trial","Headache Relief","sensitization","2026-04-27",{"date":102,"type":48},"2026-04-28",{"date":104,"type":48},"2026-03-03",{"date":106,"type":19},"2028-11-30",{"name":108,"class":55},"University of Sao Paulo",1,{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":10,"sex":14,"minAge":64,"maxAge":115,"enrollmentInfo":116,"targetDuration":4,"studyType":20,"phases":118,"briefSummary":119,"conditions":120,"keywords":121,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":56},"100563566","NCT06617832","Trial Designs for Evaluating Migraine Treatment","Inclusion Criteria:\n\n1. Adults (18-65 years)\n2. ≥ 1-year history of migraine with or without aura according to the International Classification of Headache Disorders (ICHD-3) diagnostic criteria\n3. Known episodic migraine (≥ 1 and \\< 15 headache days with features of migraine on at least 2-8 days per month for \\> 3 months) with and without aura and diagnosed before age 50\n4. Previous or active use of triptans as acute treatment for migraine\n5. Ability to speak and read Danish\n\nExclusion Criteria:\n\n1. Chronic migraine or history of chronic migraine in the last 12 months\n2. Other concomitant primary headache types except for infrequent tension-type headache\n3. Secondary headache disorders including medication overuse headache\n4. Severe psychiatric, vascular or liver diseases\n5. Opioid or barbiturate use in the month preceding screening\n6. Current use of preventive migraine treatment (i.e., onabotulinum toxin A, and\u002For Calcitonin gene-related peptide (CGRP) monoclonal antibodies) (however, stable medical treatment with other migraine prophylactic agents is permitted, e.g. antidepressant, calcium channel blockers, beta blockers and antiepileptic drugs, 4 weeks prior to inclusion until the completion of participation in the study)\n7. Contraindications or inability to tolerate triptans\n8. Current substance use disorder\n9. Implanted metallic or electronic device in the head\n10. Cardiac pacemaker or implanted or wearable defibrillator\n11. Use of illegal psychotropic drugs less than a week before participation in the study; regarding cannabis: less than four weeks before participation in the study\n12. Current pregnancy or planned pregnancy (confirmed by pregnancy test and by use of safe contraception as defined by the Danish Medicines Agency) and lactation","65 Years",{"count":117,"type":19},128,[22],"The study aims to test interactions between drug and placebo-responses in acute migraine treatment and to assess variation in adverse events according to treatment information provided. Using a clinical within-subjects, advanced balanced placebo design, patients with episodic migraine will receive six treatment conditions in a randomized order.",[30,31,27],[25,122,123,124,125,126],"Episodic migraine","Randomized controlled trial","Balanced placebo design","Treatment effects","Adverse events","2026-04-08",{"date":129,"type":48},"2026-04-13",{"date":131,"type":48},"2024-11-13",{"date":133,"type":19},"2028-09",{"name":135,"class":55},"University of Aarhus",{"id":137,"slug":4,"hasResults":10,"nctId":138,"briefTitle":139,"officialTitle":140,"acronym":4,"eligibilityCriteria":141,"healthyVolunteers":10,"sex":14,"minAge":15,"maxAge":16,"enrollmentInfo":142,"targetDuration":4,"studyType":20,"phases":144,"briefSummary":145,"conditions":146,"keywords":147,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":151,"completionDateStruct":153,"leadSponsor":155,"locationsCount":156},"100507610","NCT05889624","Responding With Evidence and Access for Childhood Headaches","Cognitive Behavioral Therapy Via Telehealth + Amitriptyline Compared to Cognitive Behavioral Therapy Via Telehealth: Pediatric Migraine Prevention (Responding With Evidence and Access for Childhood Headaches)","Inclusion Criteria:\n\n* Diagnosis: Migraine with or without aura that meets the International Classification of Headache Disorders (ICHD) criteria 5 or presentation of continuous headache that includes migranous episodes based upon headache history obtained by site PI or designee. (includes presentation with or without medication overuse headache as well)\n* Headache Frequency: 4 or more headache days based upon prospective headache diary of 28 days prior to randomization\n* Amitriptyline Eligible: Site PI or medical staff determined participant to be eligible for clinical prescription of amitriptyline as a preventive treatment for migraine\n* English fluency: Able to complete the study visits and questionnaires in English\n\nExclusion Criteria:\n\n* Current treatment includes amitriptyline and\u002For CBT specific to headache care\n* Current prescribed preventive antimigraine medication within a period equivalent to \\\u003C 5 half-lives of that medication before entering the baseline phase\n* Current treatment with onabotulinumtoxinA (Botox) or CGRP-based monoclonal antibody medications for migraine prevention\n* Youth who are pregnant\n* Report of current or ongoing suicidal thoughts. Suicide attempt within the past six months. History of bipolar disorder, prolonged QT, or pre-existing significant constipation or gastroparesis\n* Any and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the participant",{"count":143,"type":19},400,[22],"This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world care, and will demonstrate the feasibility of Cognitive Behavioral Therapy (CBT) via telehealth for youth with migraine. The focus is on applying evidence-based care and enhancing access to it. CBT via telehealth while taking a clinically-prescribed, pill-based prevention therapy (amitriptyline) will be compared to CBT via telehealth alone.",[25,26,27,28,29,30,31,32],[34,35,36,37,39,40,41,42,43],"2026-03-04",{"date":150,"type":48},"2026-03-06",{"date":152,"type":48},"2023-08-22",{"date":154,"type":19},"2027-12-31",{"name":54,"class":55},15,{"id":158,"slug":4,"hasResults":10,"nctId":159,"briefTitle":160,"officialTitle":161,"acronym":162,"eligibilityCriteria":163,"healthyVolunteers":10,"sex":14,"minAge":115,"maxAge":4,"enrollmentInfo":164,"targetDuration":165,"studyType":166,"phases":4,"briefSummary":167,"conditions":168,"keywords":169,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":174,"lastUpdatePostDateStruct":175,"startDateStruct":177,"completionDateStruct":179,"leadSponsor":181,"locationsCount":4},"100620858","NCT07363083","Treatment Response to GON Pulsed Radiofrequency in Elderly Patients With Chronic Migraine","Predictors of Treatment Response to Greater Occipital Nerve Pulsed Radiofrequency in Older Patients With Chronic Migraine","FRAIL-GON","Inclusion Criteria:\n\n* Age 65 years or older\n\nDiagnosis of chronic migraine according to ICHD criteria\n\nPresentation to the algology clinic\n\nEligibility for greater occipital nerve pulsed radiofrequency (GON-PRF) treatment according to the study protocol\n\nAbility to provide written informed consent\n\nExclusion Criteria:\n\n* Acute headache or pain conditions\n\nMalignancy-related headache\n\nSevere cognitive or communication impairment",{"count":67,"type":19},"6 Months","OBSERVATIONAL","Headache disorders are highly prevalent in older adults, yet their management remains challenging due to comorbidities, polypharmacy, and the paucity of evidence derived from geriatric populations. Most randomized clinical trials exclude elderly patients, underscoring the need for effective and safe non-pharmacological treatment strategies for headache in this age group.\n\nGreater occipital nerve blocks are commonly used in the treatment of migraine and other headache disorders; however, their clinical benefit is often transient. Pulsed radiofrequency (PRF) has been introduced as a minimally invasive technique aimed at prolonging therapeutic effects through neuromodulation without causing structural neural damage. Although greater occipital nerve pulsed radiofrequency (GON-PRF) has demonstrated efficacy in various headache disorders, its effectiveness in patients aged 65 years and older has not been adequately investigated.\n\nThe primary aim of this study is to evaluate the effectiveness of GON-PRF in patients aged ≥65 years with chronic migraine by assessing changes in pain intensity, monthly headache days, and monthly severe headache days. The secondary aim is to identify geriatric predictors of treatment response, including frailty status and the Geriatric Nutritional Risk Index (GNRI), in order to support individualized treatment strategies for older adults.",[27],[170,171,172],"Migraine Headache","Elderly, Frail","Nerve Blockade","NOT_YET_RECRUITING","2026-02-06",{"date":176,"type":48},"2026-02-10",{"date":178,"type":19},"2026-03-01",{"date":180,"type":19},"2027-05-01",{"name":182,"class":55},"Ankara City Hospital Bilkent",{"id":184,"slug":4,"hasResults":10,"nctId":185,"briefTitle":186,"officialTitle":186,"acronym":4,"eligibilityCriteria":187,"healthyVolunteers":10,"sex":14,"minAge":64,"maxAge":115,"enrollmentInfo":188,"targetDuration":190,"studyType":166,"phases":4,"briefSummary":191,"conditions":192,"keywords":193,"overallStatus":173,"whyStopped":4,"lastUpdateSubmitDate":196,"lastUpdatePostDateStruct":197,"startDateStruct":199,"completionDateStruct":201,"leadSponsor":203,"locationsCount":109},"100595903","NCT07038499","Prevalence and Determinants of Migraine Among Headache Patients","Inclusion Criteria:\n\n• Patients diagnosed with headache according to the International Classification of Headache Disorders, 3rd Edition (ICHD-3).\n\nExclusion Criteria:\n\n* Patients with other major diseases or severe mental disorders;\n* History of endocrine, immune, or nervous system diseases or other severe somatic diseases.",{"count":189,"type":19},158,"1 Day","Migraine is a prevalent and disabling neurological condition that often coexists with other health issues, such as hypertension and impaired physical, mental, and social functioning. Understanding the prevalence of migraine and its associations with these health domains can provide valuable insights into the broader impact of migraine on overall well-being. By focusing on patients at the Affiliated Hospital of Hebei University of Engineering in China, this study can identify specific health burdens within this population, inform integrated clinical management strategies, and support the development of targeted interventions to improve patient outcomes and quality of life.",[74],[194,25,28,195],"Pain","Disability","2025-06-25",{"date":198,"type":48},"2025-06-26",{"date":200,"type":19},"2025-06-23",{"date":202,"type":19},"2025-10-31",{"name":204,"class":55},"Universiti Tunku Abdul Rahman",{"id":206,"slug":4,"hasResults":10,"nctId":207,"briefTitle":208,"officialTitle":209,"acronym":4,"eligibilityCriteria":210,"healthyVolunteers":10,"sex":14,"minAge":64,"maxAge":4,"enrollmentInfo":211,"targetDuration":4,"studyType":20,"phases":213,"briefSummary":214,"conditions":215,"keywords":4,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":216,"lastUpdatePostDateStruct":217,"startDateStruct":219,"completionDateStruct":221,"leadSponsor":223,"locationsCount":109},"100560996","NCT06584409","Migraines Accepted Laser Acupuncture Compared in Blood Test of MMP2 and CGRP","The Comparsion of Primary Headache in Blood Test of MMP2 and CGRP: A Single Blind Randomized Sham-laser-acupuncture Controlled Study.","Inclusion Criteria:\n\n* Migraine patient under the diagnosis and classification of headache was evaluated using the ICHD-3 criteria.\n\nExclusion Criteria:\n\n* Age under 18 years old\n* Pregnancy",{"count":212,"type":19},60,[22],"Aims:\n\nTo investigate the efficacy of laser-acupuncture for the severity of primary headache and comorbidities, and the Lab data examination.\n\nMethods:\n\nIn this hospital-based prospective single blind randomized sham-controlled study, patients over 18 years old with primary headache will be randomly divided into two treatment arms including laser-acupuncture and sham-controlled group. The expected laser-acupuncture protocol will be bilateral BL2, GB20, EX-HN5, GB8, LI4, LR3 and midline EX-HN3 in totally eight sessions at the first month. In the sham-laser-acupuncture group, patients will receive eight sessions of laser-acupuncture for free after unblinding. We expected to track patients for at least half year. The diagnosis and classification of headache was evaluated using the ICHD-3 criteria. The severity of headache was evaluated using Migraine Disability Assessment (MIDAS) and headache diary provided by Taiwan Headache Society. The co-primary efficacy end points are change in migraine days per month and variation of MIDAS. The secondary end point is the reducing of the severity of comorbidities including headache related anxiety and depression, and both of the quality of life and sleep.\n\nIn addition, patients' characteristics will be investigated as follows:\n\n1. Sociodemographic factors (ethnicity, age, sex, body weight, BMI, blood pressure)\n2. Headache related parameters (onset, duration, pain scale, current medication for headache, menstrual cycle)\n3. Anxiety, evaluate by Hospital Anxiety and Depression Scale (HADS)\n4. Depression, evaluate by Beck's Depression Inventory\n5. Quality of life, evaluate by 36-Item Short Form Survey (SF-36)\n6. Quality of sleep, evaluate by Pittsburgh Sleep Quality Index (PSQI)\n7. Aura of headache\n8. Episodic or chronic headache (If patient diagnosed as migraine.)\n9. Nausea, vomiting, photophobia, phonophobia (If patient diagnosed as migraine.) During the following time, we will need the patient's blood samples four times, each times 20cc, all need 80cc for Lab test of MMP2, CGRP, substance P, beta-endorphin.\n\nImportance:\n\nIn our hospital, we perform laser-acupuncture for patients with headache for several years. A prospective randomized controlled study is the key tools to establish the efficacy of laser-acupuncture for primary headache, and the Lab data with MMP2, CGRP, substance P, beta-endorphin for approval. Look forward to help improve therapeutic strategies in clinical practice.",[27],"2025-04-06",{"date":218,"type":48},"2025-04-08",{"date":220,"type":48},"2025-04-07",{"date":222,"type":19},"2027-12-01",{"name":224,"class":55},"Taichung Veterans General Hospital",{"id":226,"slug":4,"hasResults":10,"nctId":227,"briefTitle":228,"officialTitle":229,"acronym":230,"eligibilityCriteria":231,"healthyVolunteers":232,"sex":14,"minAge":233,"maxAge":234,"enrollmentInfo":235,"targetDuration":190,"studyType":166,"phases":4,"briefSummary":237,"conditions":238,"keywords":244,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":247,"lastUpdatePostDateStruct":248,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":109},"100567944","NCT06674772","Molecular Phenotyping of Migraine Patients According to Sex and Age Through CGRP Quantification","Fenotipado Molecular De Pacientes Con Migraña Según Edad Y Sexo a Través De La Cuantificación De CGRP En Saliva Para Realizar Medicina De Precisión: Estudio FAST","FAST","Inclusion Criteria:\n\n* Migraine patients according to ICHD-3 criteria\n* Healthy controls paired to patient age and sex, without headache and without first degree family history of headache.\n\nExclusion Criteria:\n\n* Presence of any major medical or neurological illness.\n* Presence of any salivary gland malfunction.\n* Abuse or dependence to tobacco, alcohol or any drug in the previous 12 months before the enrollment.\n* Active migraine preventive treatment.\n* Pregnant or breastfeeding female.",true,"6 Years","75 Years",{"count":236,"type":19},440,"Patients will be asked to visit the study center 2 times, the first time for clinical assessment and a second time for sample collection. Healthy controls will only be asked to visit the study center for sample collection. A sample of blood and saliva will be collected in order to measure CGRP levels and DNA and hormone testing.",[74,28,170,239,31,240,241,242,243],"Migraine with Aura","Episodic Migraine","Chronic Migraine Headache","Chronic Migraine, Headache","Episodic Migraine Headache",[28,245,246],"CGRP","saliva","2024-11-11",{"date":131,"type":48},{"date":250,"type":48},"2022-11-29",{"date":252,"type":19},"2025-05",{"name":254,"class":55},"Hospital Universitari Vall d'Hebron Research Institute",{"id":256,"slug":4,"hasResults":10,"nctId":257,"briefTitle":258,"officialTitle":258,"acronym":4,"eligibilityCriteria":259,"healthyVolunteers":232,"sex":14,"minAge":64,"maxAge":4,"enrollmentInfo":260,"targetDuration":4,"studyType":20,"phases":262,"briefSummary":263,"conditions":264,"keywords":266,"overallStatus":44,"whyStopped":4,"lastUpdateSubmitDate":267,"lastUpdatePostDateStruct":268,"startDateStruct":270,"completionDateStruct":272,"leadSponsor":274,"locationsCount":109},"100546700","NCT06398353","Investigating the Impact of Acupuncture on the Quality of Life of Primitive Headaches Patients","Inclusion Criteria:\n\n1. Willing to sign a written subject consent form\n2. Male or female over 18 years old\n3. Those who have headaches (for example: dizziness, heavy head, dizziness, head fullness, migraine), those who have headaches more than twice a week, and whose NRS score is ˃ 4.\n4. Headache definition: Headache symptoms are classified according to the ICHD-3 headache classification of the International Headache Organization, and are mainly primary headaches.\n\nDr. Chang ,Y.-J. and Dr. Yang ,C.-C. help to exclude headache patients with the following exclusion conditions to reduce the risk to subjects.\n\nExclusin Criteria\n\n1. Pregnant women\n2. Various acute and chronic infectious diseases, various skin ulcers, sores, burns, etc.\n3. The patient has injuries to the radial artery or wrist, or has steel nails, plates, or fractures.\n4. Various types of headaches related to anatomical structural lesions\n5. Headaches associated with taking or withdrawing from substances (drugs, food, or other chemicals)\n6. Headaches related to non-head infections and metabolic diseases\n7. People with painful cranial neuropathy, other facial pain and other headaches\n8. People with secondary headaches according to ICHD-3 beta\n9. Other patients who have been evaluated by physicians as not suitable for inclusion in the evaluation.",{"count":261,"type":19},120,[22],"Primary headache is one of the most common neurological diseases in modern society, which seriously affects the patient's quality of life. Although the use of painkillers can alleviate primary headache symptoms, it may also cause drug dependence. Therefore, alternative therapies that do not rely on drugs have attracted increasing attention in recent years. Among them, acupuncture has been partially recognized by the public as an effective treatment for primary headaches. However, there is currently no scientific evidence that acupuncture is effective for primary headaches. The purpose of this project is to verify the effect of acupuncture in treating primary headaches. This study has three sub-projects:\n\nSubproject 2 explores the impact of acupuncture on headache severity and quality of life in patients with primary headaches. We evaluate the quality of life before and after acupuncture treatment through professional questionnaires, including the Numerical rating scale (NRS), headache diary, depression, anxiety and stress scale (DASS-21), health quality of life measurement questionnaire, Migraine Disability Assessment Scale and SF-36 Taiwan version. Finally, these data will be combined with the pulseway analysis from the results of sub-project 1 to provide a comprehensive way to evaluate the treatment effect.",[265],"Headache Migraine",[25,28],"2024-05-05",{"date":269,"type":48},"2024-05-07",{"date":271,"type":48},"2024-01-31",{"date":273,"type":19},"2028-05-31",{"name":275,"class":55},"Chang Gung Memorial Hospital",""]